Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1097 Results for "
Bioavailability
" in MedChemExpress (MCE) Product Catalog:
Products (1097)
1097 Results for "Bioavailability" in MCE Product Catalog:
Cat. No.: HY-168376
CAS No.: 1092676-99-7
Synonyms: 9(10)-Nitrated oleic acid
Target:
Research Areas:
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .
Cat. No.: HY-168715
CAS No.: 2894017-46-8
Target:
Research Areas:
SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2 with an IC50 of 1.2 μM. In cellular studies, SHP2-IN-33 demonstrates antiproliferative activity with an IC50 of 38 μM against Huh7 cells by arresting the G0/G1 cell cycle, promoting apoptosis (Apoptosis), and suppressing the MAPK signaling pathway. In an in vivo Huh7 xenograft mouse model, SHP2-IN-33 exhibits significant antitumor activity and favorable pharmacokinetics, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 is a promising compound for studying tumor diseases associated with SHP2 .
Cat. No.: HY-177840
Target:
Research Areas:
Liposomal Curcumin is a specialized delivery system that encapsulates Curcumin (HY-N0005) within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of Curcumin. Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
The product size below only indicate the effective content of Curcumin.
The product size below only indicate the effective content of Curcumin.
Cat. No.: HY-184414
Target:
Research Areas:
BMS-135-L-Lys is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys can be used in related research on colon cancer and lung cancer .
Cat. No.: HY-184414A
Target:
Research Areas:
BMS-135-L-Lys TFA is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys TFA achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys TFA is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys TFA can be used in related research on colon cancer and lung cancer .
Cat. No.: HY-184414B
Target:
Research Areas:
BMS-135-L-Lys dihydrochloride is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys dihydrochloride achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys dihydrochloride is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys dihydrochloride can be used in related research on colon cancer and lung cancer .
Cat. No.: HY-188081
CAS No.: 3112733-78-2
Target:
Research Areas:
YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma .
Cat. No.: HY-B0197AR
CAS No.: 143388-64-1
Synonyms: GR-85548A hydrochloride (Standard)
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan (GR-85548A) hydrochloride (Standard) is the analytical standard of Naratriptan hydrochloride (HY-B0197A). This product is intended for research and analytical applications. Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .
Cat. No.: HY-B0197AS
CAS No.: 1190021-64-7
Synonyms: GR-85548A d3
Cat. No.: HY-B0197S
CAS No.: 1190043-69-6
Synonyms: GR-85548A-d3-1
Cat. No.: HY-W698249R
CAS No.: 299-29-6
Target:
Ferrous gluconate (Standard) is the analytical standard of Ferrous gluconate. This product is intended for research and analytical applications. Ferrous gluconate is a highly water-soluble iron-containing agent with high bioavailability and bactericidal activity. As a non-heme iron, Ferrous gluconate is used for meat product fortification and improvement of iron deficiency anemia. Ferrous gluconate induces ferroptosis in E. coli through Fe 2+ infiltration, reactive oxygen species burst, lipid peroxidation and direct interaction with DNA. Ferrous gluconate also downregulates the SOS responsive transcriptional repressor LexA. In addition, Ferrous gluconate regulates multiple key pathways in E. coli such as fatty acid metabolism, iron-sulfur cluster assembly and pyruvate metabolism, and is applied in studies related to *E. coli* infection and iron deficiency anemia .
Cat. No.: HY-L035
5,148 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE Drug Repurposing Compound Library contains 5,148 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.
Cat. No.: HY-L022M
3,236 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.
Cat. No.: HY-L230
331 compounds
Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development.
Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.
Cat. No.: HY-L022
3,236 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
Cat. No.: HY-168954
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
Cat. No.: HY-184389
Target:
Research Areas:
PROTAC HDAC6 degrader 10 is a highly efficient, safe and selective HDAC6 PROTAC degrader with a pIC50 of 8.75 and a pDC50 of 9.2 in BEAS-2B cells. PROTAC HDAC6 degrader 10 recruits cereblon to form a ternary complex with HDAC6, thereby achieving the degradation of HDAC6. PROTAC HDAC6 degrader 10 significantly induces hyperacetylation of α-tubulin without affecting the acetylation of H3, and achieves sustained HDAC6 knockdown in mouse lung tissues. PROTAC HDAC6 degrader 10 exhibits high bioavailability after subcutaneous administration in mice. PROTAC HDAC6 degrader 10 enables the study of HDAC6 pharmacology via chemical knockdown of HDAC6 in vitro and in vivo, and can be used for research on pulmonary diseases .
Cat. No.: HY-187618
CAS No.: 1508276-29-6
Target:
Research Areas:
GRC-17536 is a TRPA1 antagonist with selective inhibition of TRPA1-mediated calcium influx .GRC-17536 binds to TRPA1 binding site 2 to inhibit channel activity .GRC-17536 reduces irritant-induced cough responses and citric acid-induced cough responses .GRC-17536 exhibits antitussive activity .GRC-17536 has poor pharmacokinetic and bioavailability properties, leading to discontinued development after a Phase IIa study .GRC-17536 can be used for the research of painful diabetic polyneuropathy, peripheral diabetic neuropathy, asthma, and chronic cough .
Cat. No.: HY-L033
370 compounds
Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery.
MCE Peptidomimetic Library contains 370 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.
Cat. No.: HY-L066
3,750 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,750 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
